Inventiva SA
Company Profile
Business description
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Contact
50 rue de Dijon
Daix21121
FRAT: +33 380447500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
84
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,292.80 | 45.50 | -0.49% |
| CAC 40 | 8,188.59 | 111.59 | 1.38% |
| DAX 40 | 24,272.19 | 90.82 | 0.38% |
| Dow JONES (US) | 45,952.24 | 301.07 | -0.65% |
| FTSE 100 | 9,436.09 | 11.34 | 0.12% |
| HKSE | 25,473.09 | 415.42 | -1.60% |
| NASDAQ | 22,562.54 | 107.54 | -0.47% |
| Nikkei 225 | 47,640.98 | 636.76 | -1.32% |
| NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
| S&P 500 | 6,629.07 | 41.99 | -0.63% |
| S&P/ASX 200 | 8,995.40 | 34.60 | -0.38% |
| SSE Composite Index | 3,877.20 | 39.03 | -1.00% |